Doxycycline
Malignant Neoplasms of Independent (Primary) Multiple Sites
M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Malignant Neoplasms of Independent (Primary) Multiple Sites cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin M.D. Anderson Cancer Center | Phase 1 | CC |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 1 | CC |
Pembrolizumab M.D. Anderson Cancer Center | Phase 1 | CC |
LENVATINIB M.D. Anderson Cancer Center | Phase 1 | CC |
Capecitabine M.D. Anderson Cancer Center | Phase 1 | CC |
Clostridium Novyi-Nt M.D. Anderson Cancer Center | Phase 1 | CC |
Epirubicin M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Doxycycline is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →